- Home
- AMS vs CODX Comparison
AMS vs CODX Comparison
Compare AMS & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- CODX
- Stock Information
- Founded
- AMS 1980
- CODX 2013
- Country
- AMS United States
- CODX United States
- Employees
- AMS N/A
- CODX N/A
- Industry
- AMS Medical Specialities
- CODX Medical/Dental Instruments
- Sector
- AMS Health Care
- CODX Health Care
- Exchange
- AMS Nasdaq
- CODX Nasdaq
- Market Cap
- AMS 14.7M
- CODX 15.6M
- IPO Year
- AMS N/A
- CODX 2017
- Fundamental
- Price
- AMS $2.10
- CODX $0.38
- Analyst Decision
- AMS
- CODX Buy
- Analyst Count
- AMS 0
- CODX 2
- Target Price
- AMS N/A
- CODX $2.00
- AVG Volume (30 Days)
- AMS 26.1K
- CODX 60.8M
- Earning Date
- AMS 11-11-2025
- CODX 11-13-2025
- Dividend Yield
- AMS N/A
- CODX N/A
- EPS Growth
- AMS N/A
- CODX N/A
- EPS
- AMS N/A
- CODX N/A
- Revenue
- AMS $29,251,000.00
- CODX $1,003,653.00
- Revenue This Year
- AMS $5.06
- CODX N/A
- Revenue Next Year
- AMS N/A
- CODX $31.58
- P/E Ratio
- AMS N/A
- CODX N/A
- Revenue Growth
- AMS 26.61
- CODX N/A
- 52 Week Low
- AMS $2.01
- CODX $0.23
- 52 Week High
- AMS $3.59
- CODX $1.55
- Technical
- Relative Strength Index (RSI)
- AMS 36.94
- CODX 47.83
- Support Level
- AMS $2.02
- CODX $0.43
- Resistance Level
- AMS $2.38
- CODX $0.51
- Average True Range (ATR)
- AMS 0.09
- CODX 0.14
- MACD
- AMS -0.02
- CODX -0.01
- Stochastic Oscillator
- AMS 22.22
- CODX 5.56
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.